Skip to content

The effect of salacinol, indigestible dextrin, epigallocatechin gallate, monoglucosylrutin, and phlorotannin on reduction of body fat/abdominal fat (visceral fat/subcutaneous fat)/body weight/waist circumference, BMI - A systematic review.

The effect of salacinol, indigestible dextrin, epigallocatechin gallate, monoglucosylrutin, and phlorotannin on reduction of body fat/abdominal fat (visceral fat/subcutaneous fat)/body weight/waist circumference, BMI - A systematic review. - The effect of salacinol, indigestible dextrin, epigallocatechin gallate, monoglucosylrutin, and phlorotannin on reduction of body fat/abdominal fat (visceral fat/subcutaneous fat)/body weight/waist circumference, BMI - A systematic review.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050782
Enrollment
Unknown
Registered
2024-04-30
Start date
2023-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult volunteers with a BMI greater than or equal to 25 and less than 30 and not suffering from any diseases. We will exclude minors, pregnant women, and lactating women.

Interventions

None listed

Sponsors

FUJIFILM Corporation
Lead Sponsor
Yakujihou Marketing Jimusho Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A systematic literature search is performed through scientific and clinical trial registries databases. The selection criteria are as follows. P: Healthy adult volunteers a BMI greater than or equal to 25 and less than 30 and not suffering from any diseases. We will exclude minors, pregnant women, and lactating women. I: Intake the foods containing salacinol, indigestible dextrin, epigallocatechin gallate, monoglucosyl rutin, and phlorotannin. C: The control food is a placebo food that does not contain salacinol, indigestible dextrin, epigallocatechin gallate, monoglucosyl rutin, and phlorotannin. O: The primary outcome is the effect on reduction of body fat / abdominal fat (visceral fat / subcutaneous fat) / body weight / waist circumference / BMI.

Exclusion criteria

Exclusion criteria: The literature which does not meet the key inclusion criteria will be excluded. Intervention tests without a placebo intake group are excluded.

Design outcomes

Primary

MeasureTime frame
The primary outcome is the effect on reduction of body fat/abdominal fat (visceral fat / subcutaneous fat) / body weight/waist circumference / BMI.

Countries

Japan

Contacts

Public ContactHitomi Saito

FUJIFILM Corporation Bio Science & Engineering Laboratories

hitomi.saito@fujifilm.com080-2119-4836

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026